Pulse Biosciences (PLSE) Stock Price
Pulse Biosciences Price
Revenue has compounded at 20.0% per year over the past 9 years to 350,000.00 USD. Pulse Biosciences's net margin stands at -20,794.6%, up from -43,628.9% several years earlier. Analysts set a median price target of 44.00 USD, implying 15.8% below the current price. Of 12 analysts, 11 rate the stock a buy — an overall Buy consensus.
Pulse Biosciences stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Pulse Biosciences business model & stock analysis
Frequently asked questions about Pulse Biosciences
The business model of Pulse Biosciences Inc revolves around the development and commercialization of a proprietary bioelectric technology called Nano-Pulse Stimulation (NPS). NPS is designed to selectively disrupt and kill cells, with potential applications in various medical and aesthetic procedures. Pulse Biosciences aims to leverage NPS technology across multiple therapeutic areas, including dermatology, oncology, and immune-oncology. By harnessing the power of electrical energy and using it to safely and effectively treat diseases, Pulse Biosciences seeks to revolutionize the field of medicine.
Pulse Biosciences Inc is primarily active in the medical technology industry.
The main competitors of Pulse Biosciences Inc in the market include medical technology companies such as Medtronic, Johnson & Johnson, and Boston Scientific Corporation. These companies also focus on developing innovative medical devices and therapies for various healthcare applications. However, Pulse Biosciences Inc distinguishes itself through its proprietary technology known as Nano-Pulse Stimulation (NPS), which offers unique advantages in the treatment of various dermatological conditions.
Pulse Biosciences Inc., a pioneering bioelectric medicine company, was founded in 2014. Headquartered in California, it aims to improve patients' lives through its innovative Nano-Pulse Stimulation (NPS) technology. Pulse Biosciences focuses on the development and commercialization of medical devices that utilize NPS to enhance tissue interactions and treat a variety of dermatological conditions, immune-oncology, and oncology. This revolutionary technology has the potential to transform the healthcare industry by providing safe, effective, and non-thermal treatments. With its strong emphasis on research and development, Pulse Biosciences Inc. strives to redefine medical possibilities and revolutionize patient care.
Pulse Biosciences Inc has achieved several significant milestones. Firstly, the company received clearance from the U.S. Food and Drug Administration (FDA) for its Nano-Pulse Stimulation (NPS) platform, which is a breakthrough technology for treating various dermatological conditions. Additionally, Pulse Biosciences has successfully completed several clinical trials, demonstrating the safety and efficacy of its NPS platform. The company has also expanded its intellectual property portfolio, securing multiple patents to protect its innovative technology. Moreover, Pulse Biosciences has formed strategic collaborations with renowned research institutions and medical centers to further develop and commercialize its NPS platform. These achievements highlight Pulse Biosciences Inc's progress and commitment to revolutionizing dermatological treatments.
Pulse Biosciences Inc is primarily present in the United States.
Pulse Biosciences Inc represents a commitment to innovation and cutting-edge technology in the field of medical biosciences. As a leading provider of medical therapy solutions, the company emphasizes a corporate philosophy centered around delivering breakthrough treatments to patients through its proprietary technology platform, known as Nano-Pulse Stimulation (NPS). Pulse Biosciences Inc remains dedicated to advancing the field of dermatology and oncology by providing safe and effective treatment options with its non-thermal, tumor-focused approach. With its strong focus on research and development, Pulse Biosciences Inc continues to push boundaries and revolutionize the way medical therapies are delivered.
Analysts currently set an average price target of 45.25 USD for the Pulse Biosciences stock (median: 44.00 USD), implying -13.4 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Pulse Biosciences stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Pulse Biosciences to generate revenue of 2.04 M USD and earnings per share of -1.19 USD.
Converted at the current exchange rate, the Pulse Biosciences share trades at 46.66 EUR (52.24 USD).
The Pulse Biosciences share (PLSE) is listed on 4 stock exchanges, including: NASDAQ (PLSE), Frankfurt (6L8.F), München (6L8.MU), Düsseldorf (6L8.DU).
Pulse Biosciences Inc is a medical technology company specializing in the development of non-invasive devices for the treatment of skin diseases and cancer. The company has three main business segments: CellFX System, Nano-Pulse Stimulation (NPS), and Ignite platform. The CellFX System delivers short, non-thermal electrical pulses precisely to the skin for the treatment of various dermatological conditions. NPS technology is used in cancer treatment to destroy cancer cells without damaging surrounding tissue. The Ignite platform includes the PulseCheck imaging and diagnostic device for accurate diagnosis and treatment planning. Pulse Biosciences Inc aims to provide better treatment experiences for patients and doctors and plans to market and distribute its technologies worldwide.
The expected revenue of Pulse Biosciences is 2.04 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pulse Biosciences is -80.40 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pulse Biosciences is currently -43.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pulse Biosciences stock.
The price-to-sales ratio (P/S) of Pulse Biosciences is currently 1,727.26. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pulse Biosciences stock.
The Eulerpool Quality Score for Pulse Biosciences is 4/10.
The ISIN of Pulse Biosciences is US74587B1017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Pulse Biosciences is A2AMY9. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Pulse Biosciences is PLSE. The ticker symbol is used to trade Pulse Biosciences shares on the stock exchange.
Pulse Biosciences stock
Pulse Biosciences Peer Group
Pulse Biosciences Ticker
Pulse Biosciences FIGI
All fundamentals and in-depth analysis of Pulse Biosciences
Our stock analysis for Pulse Biosciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pulse Biosciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.